Are prostate biopsies mandatory in patients with prostate-specific antigen increase during intravesical immuno- or chemotherapy for superficial bladder cancer?

Prostate

Volumn 68, Issue 11, 2008, Pages 1241-1247

  Beltrami, Paolo ^a   Ruggera, Lorenzo ^a,b   Cazzoletti, Lucia ^a   Schiavone, Dionisio ^a   Zattoni, Filiberto ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Divisione Clinicizzata di Urologia   (Italy)

Author keywords

Bladder neoplasm; Intravesical chemotherapy; Intravesical immunotherapy; Prostate biopsy; Prostate neoplasm; Prostate specific antigen

Indexed keywords

BCG VACCINE; EPIRUBICIN; IMMUNOMODULATING AGENT; MITOMYCIN C; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SURGERY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; BIOPSY; DRUG MONITORING; EPIRUBICIN; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MITOMYCIN; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATITIS; UNNECESSARY PROCEDURES; URINARY BLADDER NEOPLASMS;

EID: 48749128091     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20790     Document Type: Article

References (20)

1. Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C. European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 2002;24:105-112.
2. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A combined analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-1970.
3. Bohle A, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: Formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-687.
4. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parkmar MK, Bijnens L. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996;156:1934-1941.
5. Schellhammer PF, Lagada LE, Fillion MB. Bacillus Calmette-Guérin for superficial transitional cell carcinoma of the bladder. J Urol 1986;135:261-264.
6. Lamm D. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology 1995;9:947-952.
7. Mungan NA, Witjes JA. Bacille Calmette-Guérin in superficial transitional cell carcinoma. Br J Urol 1998;82:213-223.
8. Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG. Complications of bacillus Calmette-Guérin immunotherapy in 1,278 patients with bladder cancer. J Urol 1986;135:272-274.
9. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
10. Elkabani M, Greene JN, Vincent AL, VanHook S, Sandin RL. Disseminated Mycobacterium Bovis after intravesicular Bacillus Calmette-Guérin treatments for bladder cancer. Cancer Control 2000;7(5):476-481.
11. Bornet P, Pujade B, Lacaine F, Bazelly B, Paquet JC, Roland J, Huguier M. Tuberculous aneurysm of the femoral artery: A complication of bacille Calmette-Guerin vaccine immunotherapy: A case report. J Vasc Surg 1989;10:688-692.
12. Izes JK, Bihrle W III, Thomas CB. Corticosteroid-associated fatal mycobacterial sepsis occurring 3 years after instillation of intravesical bacillus Calmette-Guérin. J Urol 1993;150:1498-1500.
13. Lamm DL. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 1992;19:565-572.
14. Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitoycin C alone in patients with superficial bladder cancer. J Urol 1999;161:1668-1671.
15. Kuroda M, Niijiama T, Kotake T, Akaza H, Hinotsu S. 6th Trial of the Japanese Urological Cancer Research Group: Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer - The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): A randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml. Eur Urol 2004;45:600-605.
16. Leibovici D, Zisman A, Chen-Levyi Z, Cypele H, Siegel YI, Faitelovich S, Lindner A. Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin. J Urol 2000;164:1546-1549.
17. Santos Arrontes D, Lujan Galan M, Pascual Mateo C, Chiva Robles V, Fernandez Gonzalez I, Berenguer Sanchez A. Descriptive analysis of adverse events associated with transrectal prostatic biopsy after 603 procedures. Arch Esp Urol 2004;57:601-605.
18. Bowyer L, Hall RR, Reading J, Marsh MM. The persistence of bacille Calmette-Guerin in the bladder after intravesical treatment for bladder cancer. Br J Urol 1995;75:188-192.
19. Linn R, Klimberg IW, Wajsman Z. Persistent acid-fast bacilli following intravesical bacillus Calmette-Guerin. J Urol 1988;141:1197-1198.
20. Mukamel E, Konichezky M, Engelstein D, Cytron S, Abramovici A, Servadio C. Clinical and pathological findings in prostates following intravesical bacillus Calmette-Guerin instillations. J Urol 1990;144:1399-1400.